Leading design firm delivers flexible, customized lab and collaboration spaces to bolster Crinetics’ endocrine drug therapy research, development and commercialization
HGA has partnered with Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, to design and construct new lab and office spaces within Crinetics’ 94,230-square-foot headquarters in San Diego’s Sorrento Mesa neighborhood. Slated for delivery in multiple construction phases, the first of which was completed in January, HGA developed a total of 21,000 square feet of new chemistry and biology laboratories within the two-story building.
Crinetics leased the building at 6055 Lusk Boulevard in 2022 to deepen its world-class in-house R&D organization to fulfill their commitment to create important new therapeutic options for people living with endocrine diseases and endocrine-related tumors as well as accommodate its growing workforce, which had outgrown the 25,000-square-foot facility it formerly occupied. The new headquarters, which opened in January following the completion of the first construction phase, will include medical, analytical and formulation chemistry laboratories, as well as tissue/cell culture, radiochemistry and mass spectrometry support spaces, representing a 280 percent increase in lab square footage from its previous location.
“The scale of this project and its impact on Crinetics’ endocrine therapies is a point of pride for the HGA team,” said Trevor Wells, Science + Technology principal at HGA. “We enjoyed partnering with Crinetics’ in bringing their vision to life, with the goal of designing a collaborative, flexible and specialized lab facility to meet their multifaceted needs and evolve with their employees. Our designs ensure continuity and decrease disturbances to Crinetics’ life-changing pharmaceutical innovations as they adapt to market demands over time.”
During Phase I, HGA performed base tenant improvements. Phase II, scheduled for completion this summer, involves optimizing the layout to bring Crinetics’ office and R&D environments closer together. The design encourages more impromptu and informal collaboration by strategically placing meeting spaces between these areas to leverage the high foot traffic. Glazed glass panes were used to integrate the laboratory and office workspaces.
HGA is also undertaking specialized interior and infrastructure improvements, including the installation of a dedicated HVAC system and advanced controls for the biological and chemical laboratories, which requires a purpose-built design. The firm also established control areas to safely manage the labs’ hazardous materials. Another purpose-built room features multiple mass spectrometers and a radiochemistry lab for the handling of radioactive materials.
Crinetics and HGA are in the process of planning Phases III and IV to support future drug therapies. These phases will emphasize laboratory enhancements and design modifications, including the repurposing of a set of existing flexible chemistry and biology labs located on the building’s first floor.
Engineered for energy efficiency, including its lab equipment, the building features solar panels and LEED Silver certification. It is poised to accommodate the company’s goal of hiring up to 100 new employees in 2024, supplementing its current staff of nearly 300. The facility also features more than 20 meeting rooms, a gym, outdoor amenities and a communal pub area offering draft beer and spirits.
About HGA
HGA is a national interdisciplinary design firm committed to making a positive, lasting impact for our clients and communities through research-based, holistic solutions. We believe that great design requires a sense of curiosity—forming deep insight into our clients, their contexts, and the human condition. We are a collective of more than 1,000 architects, engineers, interior designers, planners, researchers, and strategists. Our practice spans multiple markets, including science and technology, corporate, cultural, education, local and federal government, and healthcare. Visit HGA.com or follow us on LinkedIn and Instagram.
About Crinetics
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Paltusotine, an investigational, first-in-class, oral somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and in Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics is also developing atumelnant (CRN04894), an investigational, first-in-class, oral ACTH antagonist, that is currently completing Phase 2 clinical studies for the treatment of congenital adrenal hyperplasia and Cushing’s disease. All of the company’s drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves’ disease, thyroid eye disease, diabetes and obesity.
HGA Media Contact
Michelle Nelsen, Public Relations Director
mnelsen@hga.com
